2年MRI达标治疗策略对临床缓解期类风湿关节炎患者疾病活动度与影像学进展的长期疗效:IMAGINE-RA随机试验5年随访
IMAGINE-more是对IMAGINE-RA随机试验的观察性延长期研究,共纳入131例处于临床缓解的类风湿关节炎患者,比较2年MRI达标治疗(以无骨炎为目标)联合临床缓解与仅以临床缓解为目标的传统达标治疗在5年时的疗效。第5年时,MRI达标组80%与传统组75%的患者处于DAS28-CRP缓解(OR 2.00,95%CI 0.76至5.28,p=0.16),两组分别有24%与26%无影像学进展(OR 0.70,95%CI 0.28至1.71,p=0.43)。
要点
- 5年时MRI达标组80%与传统组75%达DAS28-CRP缓解,差异无统计学意义(OR 2.00,p=0.16)
- 5年时MRI达标组24%与传统组26%无影像学进展,差异无统计学意义(OR 0.70,p=0.43)
- 2年MRI联合临床达标治疗较单纯临床达标治疗对5年缓解与影像学进展概率无影响
核心结论
- 与仅以临床缓解为目标的传统达标治疗相比,2年MRI联合临床达标治疗对长期达到DAS28-CRP缓解和避免影像学进展的概率均无影响。
研究设计与样本
- IMAGINE-more为原2年IMAGINE-RA随机试验(NCT01656278)的观察性延长期研究,每年进行临床检查与手、足X线检查。
- 共纳入131例患者,其中女性86例(67%),平均年龄61.2岁,病程9.5年,基线DAS28-CRP中位数1.9(IQR 1.6-2.2),vdHSS中位数16.0(IQR 7.0-36.0)。
- 原MRI达标治疗组59例(59%),传统治疗组72例(72%)。
- 预设共同主要结局为第5年DAS28-CRP缓解率(DAS28-CRP<2.6)和自基线无影像学进展(vdHSS≤0)。
主要发现
- 第5年MRI达标组47例(80%)vs传统组54例(75%)处于DAS28-CRP缓解(OR 2.00,95%CI 0.76至5.28;p=0.16)。
- 第5年MRI达标组14例(24%)vs传统组19例(26%)无影像学进展(OR 0.70,95%CI 0.28至1.71;p=0.43)。
- 次要结局包括影像学、MRI及临床疾病活动度指标和躯体功能5年变化。
关键数值与推荐
- DAS28-CRP缓解定义为DAS28-CRP<2.6。
- 无影像学进展定义为vdHSS自基线变化≤0。
- MRI达标治疗策略以无骨炎联合临床缓解为目标,传统策略仅以临床缓解为目标。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether a 2-year MRI treat-to-target strategy targeting the absence of osteitis combined with clinical remission, compared with a conventional treat-to-target strategy targeting clinical remission only (IMAGINE-rheumatoid arthritis (RA) trial) improves clinical and radiographic outcomes over 5 years in patients with RA in clinical remission. METHODS: IMAGINE-more was an observational extension study of the original 2-year IMAGINE-RA randomised trial (NCT01656278). Clinical examinations and radiographs (hands and feet) were obtained yearly. Prespecified coprimary outcomes at year 5 were Disease Activity Score in 28 joints C reactive protein (DAS28-CRP) remission rate (DAS28-CRP<2.6) and no radiographic progression (van der Heijde-modified Sharp score (vdHSS) ≤0) from baseline. Secondary outcomes included 5-year changes in radiographic, MRI and clinical measures of disease activity and physical function. RESULTS: In total 131 patients, 86 women (67%), mean age 61.2, disease duration 9.5 years, median baseline DAS28-CRP 1.9 (IQR 1.6-2.2) and vdHSS 16.0 (IQR 7.0-36.0) were included in the study; 59 (59%) patients from the original MRI treat-to-target group and 72 (72%) from the conventional group. At year 5, 47 patients (80%) in the MRI treat-to-target group vs 54 patients (75%) in the conventional treat-to-target group were in DAS28-CRP remission (OR 2.00 (95% CI 0.76 to 5.28); p=0.16) while 14 patients (24%) vs 19 patients (26%) had no radiographic progression (OR 0.70, (95% CI 0.28 to 1.71); p=0.43). CONCLUSION: A 2-year combined MRI and clinical treat-to-target strategy, compared with a conventional clinical treat-to-target strategy alone, had no effect on the long-term probability of achieving DAS28-CRP remission and of avoiding radiographic progression.
引用
- Møller-Bisgaard S, Hørslev-Petersen K, Ørnbjerg LM, et al. Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial. RMD Open. 2024. PMID: 38490697. doi:10.1136/rmdopen-2023-003945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。